Previous studies indicated that ADAM9 mediates cancer progression via regulating epithelial-to-mesenchymal transition (EMT) (9), shedding EGFR ligands (10), and activating EGFR/AKT signaling pathway (11). The gene discussed is AKT1; the disease is cancer.